Please assess the completion status of the following clinical trial:

Trial Title: Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy female ≥18 to ≤45 years old at the time of enrollment~* Regular monthly menstrual cycle during the last 12 months~* Good general health based on a medical history evaluation and physical examination~* No clinically significant abnormalities in laboratory tests at screening~* Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures~Exclusion Criteria:~* Intolerance to any recent oral contraceptive in the last three (3) years,~* Female subjects with a positive serum pregnancy test at screening~* Female subjects not willing to inform her sexual partner of her participation in the clinical study~* Use of any over the counter or prescription medications within the 14 days or 5 half lives (whichever is longer)~* Nicotine use eg cigarettes or equivalent during 12 months prior to day 1 and through the duration of the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Erenumab + Estrogen/Progestin Contraceptive (Type: EXPERIMENTAL): Participants received a combination oral contraceptive for 3 28-day cycles during the study.~A single 140 mg dose of erenumab was administered subcutaneously to the abdomen on day 10 of cycle 3 by a healthcare provider.

Based on this trial design, predict the completion outcome and termination type (if applicable).